Inspiremd Stock Price, News & Analysis

InspireMD (NYSE American: NSPR) announced the formation of its Scientific Advisory Board, chaired by respected interventional cardiologist Kenneth Rosenfield, M.D. The board aims to guide the company on clinical needs, technology advancements, and strategic growth. Dr. Rosenfield, a leader in vascular medicine, brings substantial expertise in carotid stenting and has participated in numerous critical clinical trials. InspireMD's CGuard EPS seeks to redefine treatment standards for carotid artery disease, leveraging innovative MicroNet technology to enhance patient outcomes.

InspireMD, Inc. (NYSE American: NSPR) announced key corporate updates on April 19, 2021. Shareholders approved a 1:15 reverse stock split, reducing shares from 118 million to approximately 7.9 million, effective after trading on April 26, 2021. The company has applied to join the Nasdaq Capital Market to enhance visibility among investors. CEO Marvin Slosman highlighted the company's robust position, buoyed by a $20.7 million capital raise for ongoing clinical trials and commercial goals around their CGuard EPS system, aimed at stroke prevention.

InspireMD announced a 1-for-15 reverse stock split effective April 26, 2021. This decision followed stockholder approval at a special meeting that day, allowing the Board of Directors to amend the Certificate of Incorporation for a reverse split within a range of 1-for-10 to 1-for-20. After the split, outstanding shares will reduce from approximately 118 million to 7.9 million, while the number of authorized shares remains at 150 million. The company warns that the reverse split could lead to a significant increase in exercise prices for outstanding warrants, affecting their trading status on NYSE American under the symbol NSPR.

InspireMD, Inc. (NSPR) announced the adjournment of its Special Meeting of Stockholders to April 14, 2021, allowing time for stockholders to vote on key proposals, including a reverse stock split. This move is aimed at facilitating the company’s transition to Nasdaq, which is expected to attract a broader range of investors. CEO Marvin Slosman emphasized that management supports this initiative and urges shareholders to participate in the voting process. InspireMD focuses on innovative medical technology to prevent strokes caused by carotid artery disease.

InspireMD, developer of the CGuard Embolic Prevention System (EPS), reported significant financial challenges for Q4 2020, with revenues declining by 84.4% to $158,000 due to a $580,000 settlement with a former distributor and COVID-19 impacts. Despite these setbacks, the company secured $20.7 million in a public offering, appointed key cardiology leaders, and improved its cash position to $12.6 million. The company aims to expand its global presence, particularly in China and Brazil, while preparing for an FDA registration trial. The net loss for Q4 2020 was $3.9 million, or $0.10 per share.

InspireMD, Inc. (NSPR) will report its fiscal Q4 and year-end 2020 financial results on March 9, 2021, before the market opens. A conference call for management to discuss the results will take place at 8:30 a.m. ET, followed by a Q&A session. Participants can pre-register for the call or join via provided dial-in numbers and a live webcast. The company utilizes MicroNet® technology in its CGuard™ Embolic Prevention System to address carotid artery disease with a focus on achieving optimal stroke-free outcomes.

InspireMD (NYSE American: NSPR) has engaged Hart Clinical Consultants to conduct a U.S. clinical trial for its CGuard Carotid Stent System. This trial is pivotal for the commercial registration of CGuard in the U.S., a key market for the device aimed at preventing strokes caused by carotid artery disease. The company has secured $20.7 million through a public offering to finance the trial, which will be overseen by lead investigator Dr. Chris Metzger. InspireMD aims to establish CGuard as a new standard of care in stroke prevention.

InspireMD (NYSE American: NSPR) has appointed Dr. Chris Metzger as the principal investigator for its upcoming FDA registration trial for the CGuard™ Embolic Prevention System (EPS). Dr. Metzger brings extensive clinical trial experience and is expected to provide significant leadership for the study. The CGuard EPS aims to address stroke prevention related to carotid artery disease, leveraging its unique MicroNet technology. InspireMD's CEO, Marvin Slosman, emphasized the importance of Dr. Metzger's role in ensuring the trial's success, which could potentially establish CGuard as a new standard in carotid artery management.

InspireMD reported the successful closing of an upsized public offering, generating approximately $20.7 million in gross proceeds. The offering included 29,032,258 Units priced at $0.62 each, each consisting of one share of Common Stock and a Series G Warrant. Furthermore, an over-allotment option led to the purchase of an additional 4,354,838 Units. The offering, managed by A.G.P./Alliance Global Partners, was registered with the SEC. Funds raised will be critical for further business development in the competitive medical device sector.